Clinical findings have shown that elevated NOTCH3 expression was a predictor of different aggressive tumor behaviours, such as advanced clinical stage and lymph node metastasis in a well-defined cohort of NSCLC patients [208] and, later, it has been found to be correlated with reduced sensitivity to platinum-based chemotherapy in NSCLC. The gene discussed is NOTCH3; the disease is non-small cell lung carcinoma.